• Home
  • News

Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $100 Million At-The-Market Offering Facility

relmada therapeutics logo

Press Release – New York, NY – April 14, 2022 – Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: “RLMD”), a late-stage biotechnology company, in a $100 million At-The-Market offering facility (“ATM”).

The shares were registered on RLMD’s Registration Statement on Form S-3 (File No. 333-264189) filed with the Securities and Exchange Commission on April 7, 2022.

Jefferies LLC acted as agent for the ATM.  

The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia and Barrett DiPaolo and associate Matt Siracusa. 

Sichenzia Ross Ference LLP
Latest posts by Sichenzia Ross Ference LLP (see all)